Zentalis Pharmaceuticals Llc (ZNTL)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $167.05M
Last updated: Nov 17, 2026 at 11:06 AM ET
Zentalis Pharmaceuticals Llc (ZNTL) Stock Forecast
Analysts expect Zentalis Pharmaceuticals Llc (ZNTL) to earn -$1.74 per share in the fiscal year ending Dec 31, 2026. Of 11 analysts, 8 rate the stock Buy or Strong Buy, 3 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 11 ratings average 2.27, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 73% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 8 | 72.7% |
| Hold | 3 | 27.3% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 11
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss.
- Fiscal year ending Dec 31, 2026
- -$1.74
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$1.53
- EPS consensus, revenue $6.78M
- Next report
- Mar 24, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.74 | -$1.86 to -$1.50 | 6 | N/A | N/A | 10 |
| Dec 31, 2027 | -$1.53 | -$2.09 to -$1.06 | 9 | $6.78M | N/A | 9 |
Quarterly Estimates
The EPS consensus falls from -$0.41 for the quarter ending Dec 31, 2026 to -$0.49 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.41 | -$0.59 to -$0.33 | 13 |
| Mar 31, 2027 | -$0.49 | -$0.63 to -$0.43 | 4 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 5 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 2 | 1 |
| Fiscal year ending Dec 31, 2027 | 3 | 0 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$2.11.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$1.74 | -$2.01 | -$2.02 | -$2.11 | -$2.11 | N/A |
| Fiscal year ending Dec 31, 2027 | -$1.53 | -$1.74 | -$1.82 | -$1.81 | -$1.80 | N/A |
| Quarter ending Mar 31, 2027 | -$0.49 | -$0.58 | -$0.62 | -$0.62 | -$0.62 | N/A |
Frequently Asked Questions About ZNTL
What is the ZNTL stock forecast?
Consensus analyst estimates put Zentalis Pharmaceuticals Llc's EPS at -$1.74 for the fiscal year ending Dec 31, 2026. The consensus rating from 11 analysts is Buy.
How do analysts rate ZNTL stock?
Of 11 analysts covering Zentalis Pharmaceuticals Llc, 0 rate it Strong Buy, 8 Buy, 3 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from ZNTL next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.74, with estimates from -$1.86 to -$1.50 from 6 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.53, with estimates from -$2.09 to -$1.06 from 9 analysts.
What revenue do analysts expect from Zentalis Pharmaceuticals Llc next year?
For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $6.78M.
How many analysts cover ZNTL?
11 analysts rate Zentalis Pharmaceuticals Llc stock, and 6 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
ZNTL pages: Overview, Earnings, Forecast, Financials, Competitors